22157.jpg
2021 U.S. Parkinson's Disease Epidemiology Report: 10-year Forecasts of Parkinson's Disease Epidemiology
August 23, 2021 04:18 ET | Research and Markets
Dublin, Aug. 23, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - US Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The report delivers an...
22157.jpg
Global Lewy Body Dementia Treatment Market (2020 to 2027) - Share, Size, Trends, Industry Analysis Report
March 19, 2021 08:03 ET | Research and Markets
Dublin, March 19, 2021 (GLOBE NEWSWIRE) -- The "Lewy Body Dementia Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Type; By Indication; By Distribution Channel; By Regions...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Initiation of Preclinical Study of SLS-004 in Parkinson’s Disease
May 28, 2020 07:01 ET | Seelos Therapeutics, Inc.
NEW YORK, May 28, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in the Benchmark Healthcare Virtual Conference
May 18, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors
May 15, 2020 10:30 ET | Seelos Therapeutics, Inc.
NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
May 12, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, May 12, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Provides Q1 2020 Business Update and Pipeline Developments
April 08, 2020 09:01 ET | Seelos Therapeutics, Inc.
NEW YORK, April 08, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Announces Closing of Public Offering of Common Stock
March 16, 2020 16:30 ET | Seelos Therapeutics, Inc.
NEW YORK, March 16, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics Receives Notice of Allowance for Composition of Matter Patent for SLS-007
March 06, 2020 08:01 ET | Seelos Therapeutics, Inc.
NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
Seelos_full logo and icon color.jpg
Seelos Therapeutics to Participate in Two Upcoming Investor Conferences in March
February 19, 2020 08:02 ET | Seelos Therapeutics, Inc.
Cowen 40th Annual Health Care Conference on March 2nd-4th in Boston, MARoth Capital 32nd Annual Conference on March 16th-17th in Laguna Niguel, CA NEW YORK, Feb. 19, 2020 (GLOBE NEWSWIRE) --...